CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Viral Specific T-cells (VSTs)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Viral Specific T-cells (VSTs) for Treatment of SARS-CoV-2/COVID-19

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) when given in the presence of COVID-19 signs and symptoms, caused by the virus SARS-CoV-2. VSTs are cells specially designed to fight viral infections. These cells are created from a blood sample collected from a donor who has recovered from COVID-19 infection. VSTs are investigational meaning that they are not approved by the Food and Drug Administration (FDA). COVID-19 is a new virus and treatment options are evolving rapidly. VSTs have been successfully used to treat many different viral infections and may be beneficial in treating COVID-19 in the absence of other treatments.

NCT04406064 Viral Infection Biological: Viral Specific T-cells (VSTs)
MeSH:Virus Diseases

Primary Outcomes

Description: Of the patients who had a VST culture initiated, successful production of VST cells is defined as meeting the protocol-defined release criteria.

Measure: Successful production of viral specific T-cells

Time: Within 30 days post culture initiation

Secondary Outcomes

Description: Presence of viral-specific T-cells in the participant's blood will be assessed by Elispot assay

Measure: Presence of viral-specific T-cells

Time: At 30 days after infusion

No related HPO nodes (Using clinical trials)